| Pregnancy |
1 |
0.95 |
| Hepatitis B Virus |
0 |
0.66 |
| Patient Safety |
0 |
0.51 |
| Antigens |
0 |
0.42 |
| COVID-19 |
0 |
0.4 |
| Pneumonia |
0 |
0.4 |
| Biologic Therapy |
0 |
0.37 |
| Mastitis |
0 |
0.31 |
| Syphilis |
0 |
0.28 |
| Bacterial Vaginosis |
0 |
0.25 |
| Community-Acquired Pneumonia |
0 |
0.25 |
| Intravenous |
0 |
0.25 |
| Viral Load |
0 |
0.25 |
| Treatment Guidelines |
0 |
0.24 |
| Hepatitis C Virus |
0 |
0.22 |
| Skin and Soft Tissue Infection |
0 |
0.21 |
| Chronic Hepatitis C Virus (HCV) |
0 |
0.19 |
| Herpes Simplex |
0 |
0.19 |
| Chronic Hepatitis |
0 |
0.18 |
| Allergy |
0 |
0.17 |
| Chlamydial Infection |
0 |
0.17 |
| Chronic Hepatitis B Virus (HBV) |
0 |
0.17 |
| Clinical Guidelines |
0 |
0.17 |
| Hepatitis |
0 |
0.17 |
| Hepatitis A |
0 |
0.17 |
| Outbreak |
0 |
0.17 |
| Polymerase Chain Reaction |
0 |
0.17 |
| Sexually Transmitted Infection |
0 |
0.17 |
| Vagina |
0 |
0.17 |
| Breastfeeding |
0 |
0.14 |
| MRSA |
0 |
0.14 |
| Antibiotics |
0 |
0.11 |
| Human Papillomavirus |
0 |
0.09 |
| Adverse Effects |
0 |
0.08 |
| Antibacterial Agents |
0 |
0.08 |
| Antiviral Agents |
0 |
0.08 |
| Aortitis |
0 |
0.08 |
| Bacteria |
0 |
0.08 |
| Birth |
0 |
0.08 |
| Breast |
0 |
0.08 |
| Central Nervous System |
0 |
0.08 |
| Cesarean Delivery |
0 |
0.08 |
| CT Scan |
0 |
0.08 |
| Dementia |
0 |
0.08 |
| Genital Wart |
0 |
0.08 |
| Hepatitis B Vaccine |
0 |
0.08 |
| Immunoglobulin G (IgG) |
0 |
0.08 |
| Inpatient Care |
0 |
0.08 |
| Interleukin |
0 |
0.08 |
| Medical Literature |
0 |
0.08 |
| Newborn |
0 |
0.08 |
| Nitric Oxide |
0 |
0.08 |
| Palmar |
0 |
0.08 |
| Patient History |
0 |
0.08 |
| Postpartum |
0 |
0.08 |
| Pupil |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Staphylococcus Aureus Infection |
0 |
0.08 |
| Thorax |
0 |
0.08 |
| Aneurysm |
0 |
0.06 |
| Staphylococcal Infection |
0 |
0.06 |
| Vaccines |
0 |
0.06 |